The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

Summary

This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).

Timeline

Start

2026-10-01

Primary completion

2029-05-31

Completion

2029-08-31

Drugs

Indications